Dr. Agarwal's Health Care Q1 FY27 PAT Rs 55 Cr, Rev Rs 614 Cr, Up 26%
Dr. Agarwal's Health Care reported Q1 FY27 consolidated results with Revenue from Operations at ₹614 Cr (up 26% YoY) and PAT at ₹55 Cr (up 44.6% YoY). The company added 18 new facilities, including a record 16 surgical facilities. M/s. S.R. Batliboi & Associates LLP were appointed as Statutory Auditors.
The strong financial performance and significant operational expansion are material positive developments for the company, likely to be viewed favorably by investors.
The company reported strong year-on-year growth in revenue, EBITDA, and profit after tax, along with significant operational expansion with new facility additions and surgeries performed.
Dr. Agarwal's Health Care Limited announced its unaudited consolidated financial results for the quarter ended June 30, 2026. Revenue from operations grew by 26.0% year-on-year to ₹614 Crores, and total income increased by 23.9% year-on-year to ₹620 Crores. The company's IND-AS EBITDA grew by 25.2% year-on-year to ₹177 Crores, with EBITDA margins at 28.5%. Profit after tax (PAT) saw a significant increase of 44.6% year-on-year, reaching ₹55 Crores, with PAT margins at 8.9%.
Operationally, the company added 18 new facilities during the quarter, bringing its total network to 304 facilities across 10 countries. A record 16 new surgical facilities were commissioned, the highest ever in a single quarter. The company performed 91,082 surgeries, a 15.5% increase year-on-year.
The Board of Directors also approved the appointment of M/s. S.R. Batliboi & Associates LLP as the Statutory Auditors until the conclusion of the 20th Annual General Meeting (AGM). M/s. KPMG Assurance and Consulting Services LLP were appointed as the Internal Auditors for the financial year 2026-27, and M/s. B Y & Associates were re-appointed as the Cost Auditors for the same period. Additionally, Orbit Healthcare Services (Mauritius) Limited, a wholly-owned subsidiary, proposed to incorporate a wholly-owned subsidiary in Nigeria.
Dr. Adil Agarwal, CEO, highlighted the exceptional quarter with record sequential quarter-on-quarter revenue growth and the highest ever launch of greenfield surgical facilities. He expressed confidence in delivering on the full-year plan.
What to do with a filing like this
Dr. Agarwal's Health Care Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Agarwal's Health Care Limited. Read the original for the full detail.